In the long-term follow-up of 3.5 years, the continuation of HER2-targeted therapies in breast cancer patients with reduced LVEF along with cardioprotective drugs and careful cardiac monitoring sessions seems to be safe. The gene discussed is ERBB2; the disease is breast cancer.